tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2015 Feb 5. doi: 10.1111/irv.12295. [Epub ahead of print]
[h=1]Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.[/h] D?ez-Domingo J[SUP]1[/SUP], Bald? JM, Planelles-Catarino MV, Garc?s-S?nchez M, Ubeda I, Jubert-Rosich A, Mar?s J, Garcia-Corbeira P, Moris P, Teko M, Abeele CV, Gillard P.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3-9 years.
[h=4]METHODS:[/h] In this follow-up of the Phase II study, we report immunogenicity persistence and safety at 24 months post-vaccination in children aged 3-9 years. The randomized, open-label study assessed two doses of H5N1 A/Vietnam/1194/2004 influenza vaccine (1?9 μg or 3?75 μg hemagglutinin antigen) formulated with AS03A or AS03B (11?89 mg or 5?93 mg tocopherol, respectively). Control groups received seasonal trivalent influenza vaccine. Safety was assessed prospectively and included potential immune-mediated diseases (pIMDs). Immunogenicity was assessed by hemagglutination-inhibition assay 12 and 24 months after vaccination; cross-reactivity and cell-mediated responses were also assessed. (NCT00502593).
[h=4]RESULTS:[/h] The safety population included 405 children. Over 24 months, five events fulfilled the criteria for pIMDs, of which four occurred in H5N1 vaccine recipients, including uveitis (n = 1) and autoimmune hepatitis (n = 1), which were considered to be vaccine-related. Overall, safety profiles of the vaccines were clinically acceptable. Humoral immune responses at 12 and 24 months were reduced versus those observed after the second dose of vaccine, although still within the range of those observed after the first dose. Persistence of cell-mediated immunity was strong, and CD4[SUP]+[/SUP] T cells with a T[SUB]H[/SUB] 1 profile were observed.
[h=4]CONCLUSIONS:[/h] Two doses of an AS03-adjuvanted H5N1 influenza vaccine in children showed low but persistent humoral immune responses and a strong persistence of cell-mediated immunity, with clinically acceptable safety profiles up to 24 months following first vaccination.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] AS03-adjuvanted; H5N1 influenza vaccine; cell-mediated immunity; children; pre-pandemic
PMID: 25652873 [PubMed - as supplied by publisher]
[h=1]Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.[/h] D?ez-Domingo J[SUP]1[/SUP], Bald? JM, Planelles-Catarino MV, Garc?s-S?nchez M, Ubeda I, Jubert-Rosich A, Mar?s J, Garcia-Corbeira P, Moris P, Teko M, Abeele CV, Gillard P.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3-9 years.
[h=4]METHODS:[/h] In this follow-up of the Phase II study, we report immunogenicity persistence and safety at 24 months post-vaccination in children aged 3-9 years. The randomized, open-label study assessed two doses of H5N1 A/Vietnam/1194/2004 influenza vaccine (1?9 μg or 3?75 μg hemagglutinin antigen) formulated with AS03A or AS03B (11?89 mg or 5?93 mg tocopherol, respectively). Control groups received seasonal trivalent influenza vaccine. Safety was assessed prospectively and included potential immune-mediated diseases (pIMDs). Immunogenicity was assessed by hemagglutination-inhibition assay 12 and 24 months after vaccination; cross-reactivity and cell-mediated responses were also assessed. (NCT00502593).
[h=4]RESULTS:[/h] The safety population included 405 children. Over 24 months, five events fulfilled the criteria for pIMDs, of which four occurred in H5N1 vaccine recipients, including uveitis (n = 1) and autoimmune hepatitis (n = 1), which were considered to be vaccine-related. Overall, safety profiles of the vaccines were clinically acceptable. Humoral immune responses at 12 and 24 months were reduced versus those observed after the second dose of vaccine, although still within the range of those observed after the first dose. Persistence of cell-mediated immunity was strong, and CD4[SUP]+[/SUP] T cells with a T[SUB]H[/SUB] 1 profile were observed.
[h=4]CONCLUSIONS:[/h] Two doses of an AS03-adjuvanted H5N1 influenza vaccine in children showed low but persistent humoral immune responses and a strong persistence of cell-mediated immunity, with clinically acceptable safety profiles up to 24 months following first vaccination.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] AS03-adjuvanted; H5N1 influenza vaccine; cell-mediated immunity; children; pre-pandemic
PMID: 25652873 [PubMed - as supplied by publisher]